| For: | Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol 2022; 28(27): 3346-3358 [PMID: 36158267 DOI: 10.3748/wjg.v28.i27.3346] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i27/3346.htm |
| Number | Citing Articles |
| 1 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. In vitro and in vivo experimental models for cancer immunotherapy study. Current Research in Biotechnology 2024; 7 doi: 10.1016/j.crbiot.2024.100210
|
| 2 |
Kimberly N. Kremer, Hadeel A. Khammash, Anjelica M. Miranda, Lauren N. Rutt, Shannon M. Twardy, Paige E. Anton, Margaret L. Campbell, Christian Garza-Ortiz, David J. Orlicky, Roberta Pelanda, Rebecca L. McCullough, Raul M. Torres. Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance. Frontiers in Immunology 2025; 15 doi: 10.3389/fimmu.2024.1497788
|
| 3 |
Lien-Hung Huang, Cheng-Shyuan Rau, Yueh-Wei Liu, Chia-Jung Wu, Peng-Chen Chien, Hui-Ping Lin, Yi-Chan Wu, Chun-Ying Huang, Ting-Min Hsieh, Ching-Hua Hsieh. Exploring the Regulatory Role of XIST-microRNAs/mRNA Network in Circulating CD4+ T Cells of Hepatocellular Carcinoma Patients. Biomedicines 2023; 11(7) doi: 10.3390/biomedicines11071848
|
| 4 |
Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treatment Reviews 2025; 141 doi: 10.1016/j.ctrv.2025.103046
|
| 5 |
Safia Obaidur Rab, R. Roopashree, Farag M. A. Altalbawy, M. Ravi Kumar, Mamata Chahar, Manmeet Singh, Aziz Kubaev, Hassan Thoulfikar A. Alamir, Faraj Mohammed, Abed J. Kadhim, Merwa Alhadrawi. Phytochemicals and Their Nanoformulations for Targeting Hepatocellular Carcinoma: Exploring Potential and Targeting Strategies. Cell Biochemistry and Function 2024; 42(8) doi: 10.1002/cbf.70013
|
| 6 |
Yusra Zarlashat, Shakil Abbas, Abdul Ghaffar. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. Cancers 2024; 16(11) doi: 10.3390/cancers16112034
|
| 7 |
Thikra Majid Muhammed, Saade Abdalkareem Jasim, Ahmed Hussein Zwamel, Safia Obaidur Rab, Suhas Ballal, Abhayveer Singh, Anima Nanda, Subhashree Ray, Ahmed Hjazi, Hatif Abdulrazaq Yasin. T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells. Naunyn-Schmiedeberg's Archives of Pharmacology 2025; 398(8) doi: 10.1007/s00210-025-04035-9
|
| 8 |
Mi Zhang, Weigang Yuan, Chun Li, Chanyuan Chen, Xiang Liu, Zhilu Ma, Yifei Xiang, Guisha Chen, Chunxu Wang, Lei Li, Lingli Wang, Zhong Xu, Chuanrui Xu. Resveratrol and N-acetylcystein reduce hepatic steatosis but enhance initiation and progression of hepatocellular carcinoma by inhibiting GST-pi-MAPK axis in mice. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1574039
|
| 9 |
Zachary J. Brown, Samantha M. Ruff, Timothy M. Pawlik. The effect of liver disease on hepatic microenvironment and implications for immune therapy. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1225821
|
| 10 |
Cromwel Tepap Zemnou, Ramelle Ngakam, Schelsea Siham Delore Tepap, Fredy Brice Nemg Simo, Fernando Berton Zanchi, Armel Jackson Seukep, Arnaud Fondjo Kouam, Nguyen Tien Huy. Integrating experimental biology, computational methods, and artificial intelligence in anticancer drug discovery: Bridging the translational gap. Computers in Biology and Medicine 2026; 213 doi: 10.1016/j.compbiomed.2026.111832
|
| 11 |
Kah Ming Wong, Yong Hui Wong, Sau Har Lee. In Silico Discovery of LL13, a Shortened Pardaxin 6 Peptide Derivative with Anti-proliferative Activity. International Journal of Peptide Research and Therapeutics 2024; 30(4) doi: 10.1007/s10989-024-10615-9
|
| 12 |
Ching-Hua Hsieh, Pei-Chin Chuang. Immune checkpoint biology in hepatocellular carcinoma (Review). Oncology Letters 2025; 30(6) doi: 10.3892/ol.2025.15322
|
| 13 |
Xiangqiong Li, Kunnu Jin, Jindong Fang, Xuan Ma, Jiamei He, Ancheng Lu, Zhuangzhuang Jia, Anhua Shi. Immune crosstalk in metabolic dysfunction-associated steatotic liver disease: interactions between innate and adaptive immunity. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1835197
|
| 14 |
Lorenza Di Marco, Federica Valerio, Yuri Maculan, Bianca Medici, Andrea Spallanzani, Massimo Dominici, Angela Dalia Ricci, Alessandro Rizzo, Massimiliano Salati. Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?. Expert Opinion on Biological Therapy 2026; 26(3) doi: 10.1080/14712598.2026.2642273
|
| 15 |
Gaocheng Wang, Jingjing Wang, Shuilin Dong, Zhanguo Zhang, Wanguang Zhang, Jianping Zhao. Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review. Experimental and Therapeutic Medicine 2024; 27(5) doi: 10.3892/etm.2024.12486
|
| 16 |
Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li. CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-66287-4
|
| 17 |
Zhanao He, Jie Zhang, Wukui Huang. Diagnostic role and immune correlates of programmed cell death-related genes in hepatocellular carcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-47560-4
|
| 18 |
Xin Wang, Jing Xu, Zhenya Jia, Guoping Sun. Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study. Medicine 2024; 103(50) doi: 10.1097/MD.0000000000040889
|
| 19 |
Lingzhen Hu, Zongren Wang, Yang Liao, Xiaomeng Jiang, Huojun Lian, Zhuoying Lin. Tumor-infiltrating T-Lymphocyte immunity-related immune tolerance and anti–programmed cell death protein 1/ligand of programmed cell death protein 1 therapy for advanced hepatocellular carcinoma. Oncology and Translational Medicine 2024; 10(4) doi: 10.1097/ot9.0000000000000041
|
| 20 |
Mona Abd El-Rahman Abu El-Makarem, Douaa Mohammed Sayed, Ragaa Abdelshaheed Matta, Mahmoud Ragab Mohamed, Manal Ameer Abd El-Malak, Nehal Ibrahim Abbas. Interaction of peripheral CD4+CD25+CD127− Tregs with prolactin in HCV hepatocellular carcinoma: oncogenic or immunogenic mechanisms. Egyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00250-2
|
| 21 |
Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi, Ling-Yun Gao. Relationships Among Serological Indicators and In Vitro High-Throughput Drug Sensitivity Screening Results in Patients with Hepatocellular Carcinoma. Combinatorial Chemistry & High Throughput Screening 2025; 28(11) doi: 10.2174/0113862073305230240611091708
|
| 22 |
Farag M.A. Altalbawy, Ahmed Hussein Zwamel, Gaurav Sanghvi, R. Roopashree, Mukesh Kumari, Aditya Kashyap, S. Gayathri, Rajashree Panigrahi. Interactions in hepatic tumor microenvironment: Potential targets and modulations for effective therapy. Pathology - Research and Practice 2025; 272 doi: 10.1016/j.prp.2025.156074
|
| 23 |
Pietro Guerra, Andrea Martini, Patrizia Pontisso, Paolo Angeli. Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma. Cancers 2023; 15(14) doi: 10.3390/cancers15143629
|
| 24 |
Xia Sheng, Jian-Min Qin. The tumor immune microenvironment in hepatocellular carcinoma: Its biological role in recurrence and metastasis. World Chinese Journal of Digestology 2026; 34(3) doi: 10.11569/wcjd.v34.i3.190
|
| 25 |
Roua Alsubki. Engineering CAR-based cellular immunotherapy for hepatocellular carcinoma: Current barriers, innovative strategies, and future directions. Critical Reviews in Oncology/Hematology 2026; 222 doi: 10.1016/j.critrevonc.2026.105304
|
| 26 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Exploration of Digestive Diseases 2023; doi: 10.37349/edd.2023.00029
|
| 27 |
Atieh Pourbagheri‐Sigaroodi, Majid Momeny, Nima Rezaei, Fatemeh Fallah, Davood Bashash. Immune landscape of hepatocellular carcinoma: From dysregulation of the immune responses to the potential immunotherapies. Cell Biochemistry and Function 2024; 42(5) doi: 10.1002/cbf.4098
|
| 28 |
Masaud Shah, Muhammad Hussain, Hyun Goo Woo. Structural insights into antibody-based immunotherapy for hepatocellular carcinoma. Genomics & Informatics 2025; 23(1) doi: 10.1186/s44342-024-00033-0
|
| 29 |
Ming Yang, Ethan Vanderwert, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li. The Important Roles of Natural Killer Cells in Liver Fibrosis. Biomedicines 2023; 11(5) doi: 10.3390/biomedicines11051391
|
| 30 |
C Uma, K Gobikanila, P R Jeyaramraja, Syraji Yonas. Metal nanoparticles in liver cancer therapy: Advances, challenges, and future directions. Next Research 2025; 2(3) doi: 10.1016/j.nexres.2025.100421
|
| 31 |
Chun-Ye Zhang, Shuai Liu, Ming Yang. Treatment of liver fibrosis: Past, current, and future. World Journal of Hepatology 2023; 15(6): 755-774 doi: 10.4254/wjh.v15.i6.755
Abstract(1297) |
Core Tip(1215) |
Full Article(HTML)(11972)
|
Full Article (PDF)-1940K(697)
|
Full Article with Cover (PDF)-4268K(373)
|
Full Article (Word)-1195K(64)
|
Full Article (XML)-339K(213)
|
Audio-303K(21)
|
Peer-Review Report-179K(187)
|
Answering Reviewers-123K(154)
|
Times Cited (87)
|
Total Visits (15849)
|
Open
|
| 32 |
Xiaodong Shen, Hechen Huang, Jianpeng Sheng, Xiaofeng Tang. HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications. Clinical and Experimental Medicine 2026; 26(1) doi: 10.1007/s10238-025-01851-4
|
| 33 |
清纯 陈. Regulatory T Cells: A Critical Factor in the Development and Progression of Hepatocellular Carcinoma. Advances in Clinical Medicine 2026; 16(06) doi: 10.12677/acm.2026.1662315
|
| 34 |
Wei Tian, Hanyao Sun, Ziqing Xu, Na Li, Xi Luo, Yang Li, Jiaqi Xu, Jiajia Tang, Yafei Luo, Jie Zhang, Chen Yuan, Shangyu Lu, Haibin Shi, Shouju Wang, Sheng Liu. Gold-embedded yolk-shell mesoporous organosilica nanocomposite for microwave-enhanced targeted chemotherapy and immune modulation in hepatocellular carcinoma. Biomaterials 2026; 324 doi: 10.1016/j.biomaterials.2025.123533
|
| 35 |
Dayangku Nordiyana B. P. Hassanel, Ankur Sharma. Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy. Clinical and Molecular Hepatology 2026; 32(2) doi: 10.3350/cmh.2025.1410
|
| 36 |
Conghua Song, Zijun Hou, Huifeng Wu, Xiaomei Li, Peipei Gong. Transcriptomic Analysis Reveals the Role of TRIM26 in Hepatocellular Carcinoma and Its Association With the Wnt/β‐catenin Signaling Pathway. Human Mutation 2026; 2026(1) doi: 10.1155/humu/3090777
|
| 37 |
Aloke Saha, Paromita Sarkar, Debjani Mukherjee, Kakali Bhadra. Targeting Chemical-induced Hepatocellular Carcinoma: Ameliorative Potential of Natural Compounds with Focus on Beta-carbolines. Mini-Reviews in Medicinal Chemistry 2026; 26(3) doi: 10.2174/0113895575415295250922074231
|
| 38 |
Alexsis Garcia, Stephen O. Mathew. Racial/Ethnic Disparities and Immunotherapeutic Advances in the Treatment of Hepatocellular Carcinoma. Cancers 2024; 16(13) doi: 10.3390/cancers16132446
|
| 39 |
Lisi Liu, Xun Duan, Baozhao Ju. Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies. Frontiers in Oncology 2026; 15 doi: 10.3389/fonc.2025.1744299
|
| 40 |
Maria Papanastasatou, Marianthi Gioulbasani, Evangelia Nakou, Alexandros Galaras, Teresa Rubio-Tomás, Iannis Talianidis, Aristides G. Eliopoulos, Pantelis Hatzis, Mihalis Verykokakis. Dual regulatory role of natural killer T cells during development of hepatocellular carcinoma. Communications Biology 2025; 8(1) doi: 10.1038/s42003-025-08872-5
|
| 41 |
Qing Liang, Qian Zhang, Wei Zhang, Rui Wang, Yinjiang Ma, Xiaoya Mai, Zhenglang Zhang, Bing Liu, Ping Lu, Huijuan Wan, Kejia Wang. Treg-γδ T cell axis determines sexual dimorphism in hepatocarcinogenesis. Nature Communications 2026; 17(1) doi: 10.1038/s41467-026-69603-w
|
| 42 |
Martina Taglieri, Linda Di Gregorio, Serena Matis, Chiara Rosa Maria Uras, Massimo Ardy, Sara Casati, Monica Marchese, Alessandro Poggi, Lizzia Raffaghello, Roberto Benelli. Colorectal Organoids: Models, Imaging, Omics, Therapy, Immunology, and Ethics. Cells 2025; 14(6) doi: 10.3390/cells14060457
|
| 43 |
Yun-Ling Du, Chang-Jiang Shi, Fang-Yuan Gao, Shou-Jun Xie, Meng-Na Zhang, Zhu-Qing Zhang, Wei Qiu, Ying Ming. Prognostic value of serum aldo-keto reductase family 1 member B10 in hepatocellular carcinoma. World Journal of Gastrointestinal Surgery 2026; 18(5): 116672 doi: 10.4240/wjgs.v18.i5.116672
|
| 44 |
Xinyan Wu, Zhigang Zhou, Qiang Cao, Yuquan Chen, Junling Gong, Qi Zhang, Yi Qiang, Yanfeng Lu, Guangzhu Cao. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1268188
|
| 45 |
Giuseppina Vizioli, Alberto Nicoletti, Daniela Feliciani, Barbara Funaro, Lorenzo Zileri Dal Verme, Francesca Romana Ponziani, Maria Assunta Zocco, Antonio Gasbarrini, Maurizio Gabrielli. Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?. Applied Sciences 2025; 15(5) doi: 10.3390/app15052279
|
| 46 |
Manaf Alsudaney, Mohammed N. Abdulhaleem, Abdelrahman M. Attia, Jessica Liu, Hasmik Adetyan, Osama Khattab, Andrew Hendifar, Alexander Kuo. Chronic inflammation and immune response in hepatocellular carcinoma: a comprehensive literature review. Journal of Cancer Metastasis and Treatment 2026; doi: 10.20517/2394-4722.2025.90
|
| 47 |
Ananya Ajith, Jonathan Evraerts, Caroline Bouzin, Davide Brusa, Makram Merimi, Mehdi Najar, Françoise Smets, Etienne Sokal, Mustapha Najimi. Progression to fibrosis and hepatocellular carcinoma in DEN CCl4 liver mice, is associated with macrophage and striking regulatory T cells infiltration. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1601215
|
| 48 |
Chuanliang Mi, Sai Liu, Zhida Chen. Redefining hepatocellular carcinoma treatment: nanotechnology meets tumor immune microenvironment. Journal of Drug Targeting 2025; 33(7) doi: 10.1080/1061186X.2025.2479757
|
| 49 |
Yunqi Xing, Junfeng Zhu. Role of cellular senescence in hepatic diseases (Review). International Journal of Molecular Medicine 2025; 56(5) doi: 10.3892/ijmm.2025.5623
|
| 50 |
Cromwel Tepap Zemnou, Ramelle Ngakam. Integrating Experimental Assays, Preclinical Models, and CRISPR-Based Functional Approaches for Cancer Drug Discovery. Cell Biochemistry and Biophysics 2026; doi: 10.1007/s12013-026-02070-8
|
| 51 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. The Roles of Myeloid-Derived Suppressor Cells in Liver Disease. Biomedicines 2024; 12(2) doi: 10.3390/biomedicines12020299
|